Brief: I-Mab Announces Phase 1B/2 Study Results Of Patients With Advanced Nsclc Receiving Uliledlimab And Toripalimab Combination Therapy

NovaBridge Biosciences

25/05/2023 23:20

May 25 (Reuters) - I-Mab  IMAB.O :
    * I-MAB ANNOUNCES ENCOURAGING PHASE 1B/2 STUDY RESULTS OF
PATIENTS
WITH ADVANCED NSCLC RECEIVING ULILEDLIMAB AND TORIPALIMAB
COMBINATION THERAPY AT ASCO 2023
    * I-MAB: RESULTS FROM ULILEDLIMAB PHASE 1B/2 CLINICAL TRIAL
WILL
BE REPORTED IN A POSTER PRESENTATION ON JUNE 3 AT ASCO 2023
    * I-MAB: IN NEWLY DIAGNOSED PATIENTS WHO WERE NOT ELIGIBLE
FOR/DECLINED CHEMOTHERAPY, 63% OF PATIENTS WITH CD73(HIGH) &
PD-L1 TPS≥1% RESPONDED TO COMBO
    * I-MAB: RESPONSE RATE WAS 31% IN ALL PATIENTS REGARDLESS OF
CD73
OR PD-L1 EXPRESSION IN THE NEWLY DIAGNOSED PATIENTS
    * I-MAB: A BIOMARKER-GUIDED PIVOTAL TRIAL IS BEING PLANNED

Source text for Eikon:  ID:nPnbdwsbRa 
Further company coverage:  IMAB.O 

 ((Reutersbriefs@thomsonreuters.com;))